AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States

Contributed by: Business Wire

Logo

Tags

Biotechnology

Health

Pharmaceutical

Clinical Trials

Oncology

AstraZeneca

More Like This

AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030

AstraZeneca Awards Funding to Eight Innovative Research Projects From Early-Career Scientists Around the World in Second R&D Postdoctoral Challenge

Sofinnova Partners Portfolio Company Amolyt Pharma to be Acquired by AstraZeneca

PR Newswire associated0

Cambrex Nears Completion of 5-year, $100-Million-Dollar Investment Plan, One Year Ahead of Schedule

PR Newswire associated0

CordenPharma Invests €900m in Transformational Peptide Platform Expansion in the USA & Europe

PR Newswire associated0

Department of Health - Abu Dhabi and AstraZeneca Expand Partnership During BIO 2024 to Establish New Rare Diseases Centre of Excellence

Merck invests €70 million to triple its antibody-drug conjugate (ADC) manufacturing capacity and upgrade 3200 m2 at its BioConjugation Center of Excellence in St. Louis, Missouri, USA. (Photo: Business Wire)

Merck Invests €70 Million to Expand ADC Manufacturing for Novel Cancer Therapies

BeiGene's flagship biologics manufacturing facility and clinical R&D center at the Princeton West Innovation Campus in Hopewell, N.J., is seen. (Photo: Business Wire)

BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World